1. The learner will understand the pathophysiological rationale for complement inhibitor therapy for myasthenia gravis
2. The learner will be able to determine appropriate application of complement inhibitor therapy for myasthenia gravis patients; and
3. The learner will become familiar with the next generation of complement inhibitors under development.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation